We are live on ! Find out more
IMGO

Imago BioSciences, Inc. Common stock
IMGO

Delisted

IMGO was delisted on the 10th of January, 2023.

Back to rankings

59 hedge funds and large institutions have $576M invested in Imago BioSciences, Inc. Common stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

13% more funds holding

Funds holding: 52 → 59 (+7)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less capital invested

Capital invested by funds: $607M → $576M (-$30.9M)

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
0.93%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
26
Reduced
14
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$41.5M
2
BlackRock
BlackRock
New York
+$40.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.71M
4
MCMC
Matrix Capital Management Company
New Hampshire
+$6.39M
5
State Street
State Street
Massachusetts
+$2.24M

Top Sellers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
-$70.4M
2
Blackstone Inc
Blackstone Inc
New York
-$19.5M
3
Millennium Management
Millennium Management
New York
-$3.6M
4
HF
HRT Financial
New York
-$1.56M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
51
Amalgamated Bank
New York
$41K +$44.5K +2,145 New
AF
52
Amalgamated Financial
New York
$41K +$44.5K +2,145 New
Citigroup
53
Citigroup
New York
$36K -$37.2K -1,794 -49%
AIP
54
Ameritas Investment Partners
Nebraska
$30K +$16.8K +809 +108%
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$28.4K +$30.6K +1,473 New
UBS Group
56
UBS Group
Switzerland
$25K -$68.1K -3,281 -72%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$24K -$14K -677 -35%
TRCT
58
Tower Research Capital (TRC)
New York
$10K -$13.5K -650 -55%
Daiwa Securities Group
59
Daiwa Securities Group
Japan
$2K – – –
FM
60
Frazier Management
Washington
– -$70.4M -2,971,274 Closed
Millennium Management
61
Millennium Management
New York
– -$3.6M -151,786 Closed
HF
62
HRT Financial
New York
– -$1.56M -65,989 Closed
D.E. Shaw & Co
63
D.E. Shaw & Co
New York
– -$760K -32,058 Closed
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
– -$335K -14,137 Closed
Squarepoint
65
Squarepoint
New York
– -$268K -11,305 Closed
1 2
3

IMGO Hedge Fund Activity: Q1 2022 in Review

59 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Imago BioSciences, Inc. Common stock (IMGO) for Q1 2022, worth a combined $576M — down 5.1% from $607M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IMGO positions and 6 closed out — a net gain of 7 holders — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $41.5M. The largest seller was Frazier Management, exiting entirely with an estimated $70.4M sold.

  • 59 institutional investors held Imago BioSciences, Inc. Common stock (IMGO) as of Q1 2022, up from 52 in Q4 2021.
  • Funds reported $576M of Imago BioSciences, Inc. Common stock stock for Q1 2022, down 5.1% quarter-over-quarter.
  • 13 funds opened new Imago BioSciences, Inc. Common stock positions in Q1 2022 and 6 closed out, a net change of +7 holders.
  • The largest Imago BioSciences, Inc. Common stock buyer in Q1 2022 was Fidelity Investments, an estimated $41.5M added.
  • The largest Imago BioSciences, Inc. Common stock seller in Q1 2022 was Frazier Management, an estimated $70.4M sold.

Based on aggregated 13F filings for Q1 2022.